Crude oil prices and UAE's role in OPEC+ are influencing Indian markets. Experts suggest oil prices may fall in the medium term, easing con...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...

Drugmakers quickly voiced their opposition to the move, but public health advocates were elated. Waiving patent rights, the thinking goes, ...

In a statement, the Hyderabad headquartered pharma company said Baricitinib in combination with Remdesivir is used for the treatment of Cov...

Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...

Cases where courts forbid Indian drugmakers from launching generic versions of patented drugs has rattled domestic pharma sector.

Justice S Ravindra Bhat and SK Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging the sing...

Despite the SC verdict, Indian generics makers won't be falling over each other to take on Big Pharma and launch cheaper versions of their ...

Cipla said in the Supreme Court that India's patent laws have been made restrictive to increase the reach of life-saving drugs.

The Delhi HC ruling favouring India’s second largest drugmaker Cipla has come as a shot in the arm for other generic makers who are fightin...

Drug firm Venus Remedies today said it has received approval from the Australian Patent office (APO) for its product 'Vancoplus'.

Earlier this week, a ruling effectively cut the price of high-cost cancer drug Sorafenib by 97%. But that’s just one of many legal battles ...

'Medicins Sans Frontieres', an international medical humanitarian group, today welcomed India's decision to reject a patent granted to Swis...

Blockbuster AIDS drug Viread is set to witness a price war in the domestic market in the next few days, benefitting lakhs of patients using...

On January 25 this year, the patent office in Chennai rejected a patent application by pharma MNC Novartis for its anti-cancer drug Glivec ...